{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:43:34Z","timestamp":1790898214229,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T00:00:00Z","timestamp":1560470400000},"content-version":"vor","delay-in-days":225,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.5604\/01.3001.0012.7200","type":"journal-article","created":{"date-parts":[[2018,11,5]],"date-time":"2018-11-05T06:32:31Z","timestamp":1541399551000},"page":"1001-1011","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Drug-Drug Interactions in Hepatitis Patients: Do these Interactions Matter in Clinical Perspectives?"],"prefix":"10.1016","volume":"17","author":[{"given":"Sidra","family":"Noor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iqbal","family":"Haider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiza","family":"Khadim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.5604\/01.3001.0012.7200_bib0005","unstructured":"Sembulingam K, Sembulingam P. (eds.) Essentials of Medical Phsyiology. 2nd Ed. New Dehli, India: Jaypee Brothers Medical Publishers, 2012; pp. 179-88."},{"key":"10.5604\/01.3001.0012.7200_bib0010","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jhep.2006.05.013","article-title":"The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide","volume":"45","author":"Perz","year":"2006","journal-title":"J Hepatol"},{"key":"10.5604\/01.3001.0012.7200_bib0015","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2165\/00002018-200528060-00005","article-title":"Dose adjustment in patients with liver disease","volume":"28","author":"Delco","year":"2005","journal-title":"Drug Saf"},{"key":"10.5604\/01.3001.0012.7200_bib0020","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2165\/00003088-197904060-00002","article-title":"Hepatic first-pass metabolism in liver disease","volume":"4","author":"Blaschke","year":"1979","journal-title":"Clin Pharmacokinet"},{"key":"10.5604\/01.3001.0012.7200_bib0025","first-page":"176","article-title":"Assessment of portal hemodynamics by ultrasound color Doppler and laser Doppler velocimetry in liver cirrhosis","volume":"21","author":"Vyas","year":"2001","journal-title":"Indian J Gastroenterol"},{"key":"10.5604\/01.3001.0012.7200_bib0030","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0009-9236(98)90017-0","article-title":"Selective effect of liver disease on the activities of specific metabolizing enzymes: Investigation of cytochromes P450 2C19 and 2D6","volume":"64","author":"Adedoyin","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.5604\/01.3001.0012.7200_bib0035","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40360-016-0053-1","article-title":"Drugdrug interactions and QT prolongation as a commonly assessed cardiac effect-comprehensive overview of clinical trials","volume":"17","author":"Wi\u0153niowska","year":"2016","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.5604\/01.3001.0012.7200_bib0040","doi-asserted-by":"crossref","first-page":"316","DOI":"10.2165\/00003495-199243030-00003","article-title":"Pharmacotherapy of ascites associated with cirrhosis","volume":"43","author":"Gin\u00e8s","year":"1992","journal-title":"Drugs"},{"key":"10.5604\/01.3001.0012.7200_bib0045","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s40121-015-0058-x","article-title":"A cross-sectional study comparing the frequency of drug interactions after adding simeprevir-or sofosbuvir-containing therapy to medication profiles of hepatitis C monoinfected patients","volume":"4","author":"Patel","year":"2015","journal-title":"Infect Dis Ther"},{"key":"10.5604\/01.3001.0012.7200_bib0050","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1097\/MEG.0000000000000152","article-title":"Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential","volume":"26","author":"Lauffenburger","year":"2014","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.5604\/01.3001.0012.7200_bib0055","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jhep.2012.10.027","article-title":"Clinical management of drug-drug interactions in HCV therapy: Challenges and solutions","volume":"58","author":"Burger","year":"2013","journal-title":"J Hepatol"},{"key":"10.5604\/01.3001.0012.7200_bib0060","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00228-011-1105-5","article-title":"Potential drug-drug interactions and adverse drug reactions in patients with liver cirrhosis","volume":"68","author":"Franz","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.5604\/01.3001.0012.7200_bib0065","doi-asserted-by":"crossref","first-page":"S343","DOI":"10.1016\/j.dld.2013.07.008","article-title":"The importance of drug-drug interactions in the DAA era","volume":"45","author":"Back","year":"2013","journal-title":"Dig Liver Dis"},{"key":"10.5604\/01.3001.0012.7200_bib0070","doi-asserted-by":"crossref","first-page":"e0172159","DOI":"10.1371\/journal.pone.0172159","article-title":"Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study","volume":"12","author":"Kondili","year":"2017","journal-title":"PLoS One"},{"key":"10.5604\/01.3001.0012.7200_bib0075","doi-asserted-by":"crossref","first-page":"e0141164","DOI":"10.1371\/journal.pone.0141164","article-title":"Potential for drug-drug interactions between antiretrovirals and HCV direct acting antivirals in a large cohort of HIV\/HCV coinfected patients","volume":"10","author":"Poizot-Martin","year":"2015","journal-title":"PLoS One"},{"key":"10.5604\/01.3001.0012.7200_bib0080","unstructured":"Micromedex Drug-Reax\u00ae, Greenwood Village, CO: Truven Health Analytics. Available at: https:\/\/ www.micromedexsolutions.com\/micromedex2\/librarian\/ssl\/ true. Accessed February 10 2017."},{"key":"10.5604\/01.3001.0012.7200_bib0085","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3163\/1536-5050.104.4.007","article-title":"Evaluation of resources for analyzing drug interactions","volume":"104","author":"Patel","year":"2016","journal-title":"J Med Libr Assoc"},{"key":"10.5604\/01.3001.0012.7200_bib0090","doi-asserted-by":"crossref","first-page":"257","DOI":"10.4103\/2279-042X.192461","article-title":"A comparison of five common drug-drug interaction software programs regarding accuracy and comprehensiveness","volume":"5","author":"Kheshti","year":"2016","journal-title":"J Res Pharm Pract"},{"key":"10.5604\/01.3001.0012.7200_bib0095","unstructured":"Tatro DS. (ed.) Drug Interaction Facts: Facts and Comparisons. St. Louis, Missouri: Wolters Kluwer Health, 2008; pp. 901-1358."},{"key":"10.5604\/01.3001.0012.7200_bib0100","unstructured":"Baxter K. (ed.) Stockley\u2019s Drug Interactions. 9th ed. London, Chicago: Pharmaceutical Press; 2010; pp.349-1123."},{"key":"10.5604\/01.3001.0012.7200_bib0105","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ejim.2007.12.002","article-title":"Prevalence of drug-drug interactions at hospital entry and during hospital stay of patients in internal medicine","volume":"19","author":"Vonbach","year":"2008","journal-title":"Eur J Intern Med"},{"key":"10.5604\/01.3001.0012.7200_bib0110","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S1130-6343(08)75950-6","article-title":"Drug-drug interactions in patients from an internal medicine service","volume":"32","author":"Ib\u00e1\u00f1ez","year":"2008","journal-title":"Farm Hosp"},{"key":"10.5604\/01.3001.0012.7200_bib0115","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s11096-013-9764-1","article-title":"Potential drug-drug interactions in internal medicine wards in hospital setting in Pakistan","volume":"35","author":"Ismail","year":"2013","journal-title":"Int J Clin Pharm"},{"key":"10.5604\/01.3001.0012.7200_bib0120","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jcrc.2017.04.028","article-title":"Potential drug-drug interactions in pediatric patients admitted to intensive care unit of Khyber Teaching Hospital, Peshawar, Pakistan: A cross-sectional study","volume":"40","author":"Ismail","year":"2017","journal-title":"J Crit Care"},{"key":"10.5604\/01.3001.0012.7200_bib0125","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.3748\/wjg.v23.i9.1618","article-title":"Optimizing hepatitis C virus treatment through pharmacist interventions: Identification and management of drug-drug interactions","volume":"23","author":"Langness","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.5604\/01.3001.0012.7200_bib0130","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s11096-012-9642-2","article-title":"Evaluation of drug-drug interaction screening software combined with pharmacist intervention","volume":"34","author":"Moura","year":"2012","journal-title":"Int J Clin Pharm"},{"key":"10.5604\/01.3001.0012.7200_bib0135","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.2165\/11316700-000000000-00000","article-title":"Laboratory tests in the clinical risk management of potential drug-drug interactions","volume":"32","author":"Geerts","year":"2009","journal-title":"Drug Saf"},{"key":"10.5604\/01.3001.0012.7200_bib0140","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2165\/00002018-200528120-00007","article-title":"Clinical relevance of drug-drug interactions","volume":"28","author":"van Roon","year":"2005","journal-title":"Drug Saf"},{"key":"10.5604\/01.3001.0012.7200_bib0145","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00228-002-0557-z","article-title":"Potential drug-drug interactions in the medication of medical patients at hospital discharge","volume":"58","author":"Egger","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"key":"10.5604\/01.3001.0012.7200_bib0150","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1111\/liv.12712","article-title":"Optimal management of patients with chronic hepatitis C and comorbidities","volume":"35","author":"Boccaccio","year":"2015","journal-title":"Liver Int"},{"key":"10.5604\/01.3001.0012.7200_bib0155","first-page":"266","article-title":"Drug-drug interactions associated with length of stay and cost of hospitalization","volume":"12","author":"Moura","year":"2009","journal-title":"J Pharm Pharmaceut Sci"},{"key":"10.5604\/01.3001.0012.7200_bib0160","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000449376","article-title":"Potentially Serious Drug-Drug Interactions in Older Patients Hospitalized for Acute Ischemic and Hemorrhagic Stroke","volume":"76","author":"Caratozzolo","year":"2016","journal-title":"Eur Neurol"},{"key":"10.5604\/01.3001.0012.7200_bib0165","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1365-2710.2007.00891.x","article-title":"Prevalence and predictors of potential drug-drug interactions in Regione Emilia-Romagna, Italy","volume":"33","author":"Gagne","year":"2008","journal-title":"J Clin Pharm Ther"},{"key":"10.5604\/01.3001.0012.7200_bib0170","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1097\/00005650-200212000-00004","article-title":"Improving recognition of drug interactions: benefits and barriers to using automated drug alerts","volume":"40","author":"Glassman","year":"2002","journal-title":"Med Care"},{"key":"10.5604\/01.3001.0012.7200_bib0175","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1177\/106002809603000902","article-title":"Quantifying the Clinical Significance of Drug\u2014Drug Interactions: Scaling Pharmacists\u2019 Perceptions of a Common Interaction Classification Scheme","volume":"30","author":"Roberts","year":"1996","journal-title":"Ann Pharmacother"},{"key":"10.5604\/01.3001.0012.7200_bib0180","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2165\/00002018-199309010-00005","article-title":"Epidemiology of drug-drug interactions as a cause of hospital admissions","volume":"9","author":"Jankel","year":"1993","journal-title":"Drug Saf"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268119310622?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268119310622?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:38:22Z","timestamp":1761647902000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268119310622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S1665268119310622"],"URL":"https:\/\/doi.org\/10.5604\/01.3001.0012.7200","relation":{},"ISSN":["1665-2681"],"issn-type":[{"value":"1665-2681","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-Drug Interactions in Hepatitis Patients: Do these Interactions Matter in Clinical Perspectives?","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.5604\/01.3001.0012.7200","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C. Published by Elsevier Espa\u00f1a, S.L.","name":"copyright","label":"Copyright"}]}}